Results 121 to 130 of about 9,615 (165)
IBRUTINIB AND ATRIAL FIBRILLATION: A BELGIAN EXPERT CONSENSUS PAPER
Over the last decade, the oral Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib induced a paradigm shift in the treatment of patients with chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), and Waldenströms macroglobulinemia (WM).
Van der Linden, L +11 more
core
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp +5 more
wiley +1 more source
Summary Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)‐based regimen.
Sydney Dubois +8 more
wiley +1 more source
Beyond Atrial Fibrillation and Heart Failure: Ibrutinib-Induced Pericardial Effusion
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has transformed the management of various hematological malignancies. However, its association with cardiovascular toxicities, particularly atrial fibrillation (AF), hypertension, and heart failure (HF ...
Singh, Anaiya +3 more
core +1 more source
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23–0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort.
Farrukh T. Awan +8 more
wiley +1 more source
International audienceObjective: Ibrutinib has been the first Bruton tyrosine kinase inhibitor (BTKi) authorized for the treatment of B-cell lymphoproliferative disorders (B-LPDs).
Beziat, Guillaume +9 more
core +1 more source
A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma
Background/Objectives: Aurora (AK) A/B are oncogenic mitotic kinases that when over-expressed are poor prognostic markers in mantle cell lymphoma (MCL). Methods and Results: Alisertib, an AK-A inhibitor, has anti-tumor activity in relapsed/refractory (r ...
Patrick J. Conway +11 more
core +1 more source
Summary While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL.
Stefano Luminari +28 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Thermodynamic characterisation of covalent ligand binding
Background and Purpose Differential scanning fluorimetry (DSF) is a common and straightforward method to evaluate the thermal stability of proteins and has been heavily used for ligand binding characterisation as well as for screening. One class of compounds that is less typically evaluated by DSF are covalent binders.
Rebecca Hertzman +4 more
wiley +1 more source

